Glenzocimab, GADOVIST 1,0 mmol/mL, solution injectable, 0.9% clinical trials

Glenzocimab in Anterior stroke with Large Ischemic Core eligible for Endovascular therapy

This study looks at a new drug, Glenzocimab, for people who have had a severe stroke. It aims to see if the drug helps people recover better three months after their stroke, especially when combined with standard clot removal procedures.